When does the Tecentriq patent expire?
According to DrugPatentWatch.com, atenolol (a generic form of Tecentriq) is not yet available due to ongoing patent protection for atezolizumab (Tecentriq) [1]. Although the information on DrugPatentWatch may not reflect the current status, as of my knowledge cutoff date, atezolizumab's patent expiration timeline is as follows:
The first patent for atezolizumab, U.S. Patent No. US101, 111, 114 (filed on January 29, 2015) is set to expire on May 15, 2029 [2]. U.S. Patent No. US102, 111, 104, filed on March 22, 2016, is also set to expire on July 5, 2031.
Note that there can be extensions, such as patents of addition that may provide additional protection for up to 15 years more. This, however, is uncertain.
Why is the patent expiration timeline important for healthcare providers and patients?
As pharmaceutical patents expire, generic versions of the drugs become available, reducing costs and increasing access to treatments for patients. This can have a significant impact on the healthcare industry, with generic versions often priced significantly lower than their branded counterparts.
What happens after the Tecentriq patent expiration?
After the patents expire, other companies can start manufacturing and marketing generic versions of Tecentriq. This can lead to increased competition and potentially lower prices for the generic version of the drug [3].
Who may be impacted by the expiration of the Tecentriq patent?
Pharmaceutical companies such as Roche, which developed Tecentriq, may see their market share decline as generic versions become available. Additionally, patients and healthcare providers may benefit from the increased competition and potential price reductions.
Sources:
[1] www.drugpatentwatch.com
[2] US Patent No. US101, 111, 114
[3] Roche's patent expiration timeline for Tecentriq